BioSpace News Archive

VBI Vaccines Inc. today announced that an abstract has been accepted for oral presentation at The International Liver Congress™ 2022 (ILC), the Annual Meeting of the European Association for the Study of the Liver (EASL), taking place June 22-26, 2022.

Scioto Biosciences, Inc. (Scioto), a clinical-stage biotechnology company dedicated to innovative research and development in the field of microbiome therapeutics for various diseases, announced top-line results of its Phase Ib trial of lead asset, SB-121.

Devonian Health Group Inc. today announced the acceptance for publication of results from its positive phase 2 trial of Thykamine™ in patients with mild-to-moderate Atopic Dermatitis.

NovoMedix, LLC (“NovoMedix”), today announced that the National Heart, Lung, and Blood Institute division of the NIH has awarded NovoMedix a $2M Phase II SBIR grant to further the development of Novel Small Molecules that protect Triple-Negative Breast Cancer (TNBC) patients from the devastating long-term cardiotoxic effects of doxorubicin chemotherapy.

Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, announces that two abstracts featuring the Company’s RAS inhibitor program will be featured in the American Society for Clinical Oncology’s (ASCO) Annual Meeting Abstract Book.

VeriSIM Life (VeriSIM) www.verisimlife.com, the leading artificial intelligence (AI)-enabled, unique R&D decisions de-risker for breakthrough drug development, today announced that it has entered into a partnership agreement with Total Brain www.totalbrain.com.

According to Vision Research Reports, the Europe mobility aids market was valued at USD 2.9 billion in 2021 and it is predicted to surpass around USD 3.99 billion by 2030 with a CAGR of 3.61% from 2022 to 2030.

Multispecific Antibodies Cumulative Sales Have Already Surpassed USD 9 Billion By 2021 Says Kuick Research In Recent Reports On Bispecific & Trispecific Antibodies.

The global nasal packing devices market was surpassed at USD 173.1 million in 2021 and is expected to hit around USD 271.2 million by 2030, growing at a CAGR of 5.12% from 2022 to 2030.

According to QY Research Medical, the longevity and anti-senescence therapy market size is projected to reach US$ 44.2 billion by 2030, growing at a CAGR of 6.4% from 2021 to 2030.